Skip to content
Screener

Inhibrx Biosciences, Inc. INBX Segment Reporting, Other Segment Item, Amount

Segment Reporting, Other Segment Item, Amount at other companies

PRA Group logo
PRA GroupPRAA
$35.48M-6.5%
ConocoPhillips logo
ConocoPhillipsCOP
$7.45B+42.3%
Matthews International logo
Matthews InternationalMATW
-$15.63M-883%
Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
$25.48M+4,316%
Radiant Logistics logo
Radiant LogisticsRLGT
-$271K-113%
Saga Communications logo
Saga CommunicationsSGA
$822.5K-12.1%

Segments

By segment

See full
Reportable Segment$2K0.0%

Other financials

Income statement

See full
Revenue--100%
Operating income-$30.9M+27.9%
Net income-$33.4M+22.8%
EPS (diluted)-$2.15+23.2%

Balance sheet

See full
Cash & equivalents$161.7M-25.3%
Total debt$180.9M+69.8%
Total equity-$21.0M-122%
Total assets$184.0M-24.2%

Cash flow

See full
Operating cash flow-$38.0M-5.9%
CapEx--100%
Free cash flow-$38.0M-5.9%

Valuation

See full
Market cap$1.3B+320%
Enterprise value$1.32B+474%

Profitability

See full
Operating margin-10,386.5%-5,025pp
Net margin-10,773.5%-878,492pp
FCF margin-9,986.5%-4,727pp

Returns & leverage

See full
Return on equity-197.8%-2,158pp
Debt / equity13.4×+13.3×
Current ratio6.5×+1.3×